Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus ARISTOSPAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus ARISTOSPAN.
A-HYDROCORT vs ARISTOSPAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
Triamcinolone hexacetonide (Aristospan) is administered intra-articularly or intralesionally. For intra-articular use in adults, typical dose is 2–20 mg (0.5–1 mL of 20 mg/mL suspension) depending on joint size. For intralesional use, 2–3 mg per injection site, with total dose not exceeding 0.5 mg/kg per day.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Category C
Category C
Corticosteroid
Corticosteroid